Orum Therapeutics
11 - 50 employees
Founded 2016
🧬 Biotechnology
⚕️ Healthcare Insurance
💊 Pharmaceuticals
Biotechnology • Healthcare Insurance • Pharmaceuticals
Orum Therapeutics is a clinical-stage biotechnology company that pioneers a novel class of antibody-drug conjugates (ADCs). The company develops innovative therapies that combine the efficacy of protein degraders with the precision of antibodies to change the landscape of disease treatment. Through its advanced TPD² cell-selective degradation technology, Orum aims to improve the efficacy, safety, and pharmacokinetics of targeted therapies.
External Research Leader – CRO
🕒 February 12
🗣️🇨🇳 Chinese Required
📊 Check your resume score for this job
Improve your chances of getting an interview by checking your resume score before you apply.
Orum Therapeutics
11 - 50 employees
Founded 2016
🧬 Biotechnology
⚕️ Healthcare Insurance
💊 Pharmaceuticals
Biotechnology • Healthcare Insurance • Pharmaceuticals
Orum Therapeutics is a clinical-stage biotechnology company that pioneers a novel class of antibody-drug conjugates (ADCs). The company develops innovative therapies that combine the efficacy of protein degraders with the precision of antibodies to change the landscape of disease treatment. Through its advanced TPD² cell-selective degradation technology, Orum aims to improve the efficacy, safety, and pharmacokinetics of targeted therapies.
📋 Description
• Oversee the external development of our Degrader-Antibody Conjugate (DAC) pipeline • Manage high-stakes projects at CROs, specifically overseeing the synthesis of proprietary molecular glue degrader payloads and their conjugation to therapeutic antibodies • Proactively identify and vet CROs that offer specialized expertise in relevant in-vitro activity assays, in vivo studies, linker-payload synthesis, and complex bioconjugation • Support the expansion of our TPD²® (Degradation) and TPS²™ (Stabilization) platforms by identifying specialized Chinese partners capable of advanced physics-based modeling and machine learning-driven payload design • Drive IND-enabling studies for candidates like ORM-1153 (CD123-targeting DAC) and support ongoing clinical-stage programs • Navigate the "China price" ecosystem to find cost-effective, high-quality alternatives for R&D without compromising the integrity of our AnDC™ (Antibody neoDegrader Conjugate) technology
🎯 Requirements
• PhD in Pharmacology, Biology, Organic/Medicinal Chemistry, or related field • Deep understanding of the E3 ubiquitin ligase pathway, linker-payload chemistry, and the nuances of antibody-mediated intracellular delivery • 7–10+ years in biotech/pharma with a track record of managing complex therapeutic modalities (ADCs, TPDs, or PROTACs) • Bilingual Fluency: Oral and written proficiency in Mandarin and English is essential for navigating local networks and communicating with global leadership • Global-Local Mindset: Must possess the "combo" background—international scientific training (U.S./Europe) coupled with significant operational experience within the Chinese regulatory and CRO landscape.
🏖️ Benefits
• Full home-office setup stipend to facilitate seamless virtual collaboration with our global R&D leadership
Apply Now
